CU6 Stock Overview
A clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Clarity Pharmaceuticals Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$5.68 |
| 52 Week High | AU$8.98 |
| 52 Week Low | AU$1.26 |
| Beta | 1.68 |
| 11 Month Change | -14.59% |
| 3 Month Change | -16.10% |
| 1 Year Change | 345.49% |
| 33 Year Change | 531.11% |
| 5 Year Change | n/a |
| Change since IPO | 283.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| CU6 | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -20.8% | -16.3% | 0.9% |
| 1Y | 345.5% | 35.0% | 17.7% |
Return vs Industry: CU6 exceeded the Australian Pharmaceuticals industry which returned 35% over the past year.
Return vs Market: CU6 exceeded the Australian Market which returned 17.7% over the past year.
Price Volatility
| CU6 volatility | |
|---|---|
| CU6 Average Weekly Movement | 9.3% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: CU6 has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: CU6's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 50 | Michelle Parker | www.claritypharmaceuticals.com |
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company’s products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. It develops theranostic therapy and imaging products for the treatment of cancer in children and adults.
Clarity Pharmaceuticals Ltd Fundamentals Summary
| CU6 fundamental statistics | |
|---|---|
| Market cap | AU$1.82b |
| Earnings (TTM) | -AU$42.32m |
| Revenue (TTM) | AU$11.51m |
158.1x
P/S Ratio-43.0x
P/E RatioIs CU6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CU6 income statement (TTM) | |
|---|---|
| Revenue | AU$11.51m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$11.51m |
| Other Expenses | AU$53.83m |
| Earnings | -AU$42.32m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 100.00% |
| Net Profit Margin | -367.83% |
| Debt/Equity Ratio | 0% |
How did CU6 perform over the long term?
See historical performance and comparison